Results 61 to 70 of about 4,412 (151)

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

Vaccine: X, 2023
Background: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes.
Stephanie Montero, Diego Urrunaga-Pastor, Percy Soto-Becerra, Aleksandar Cvetkovic-Vega, Martina Guillermo-Roman, Luis Figueroa-Montes, Arturo A. Sagástegui, Sergio Alvizuri-Pastor, Roxana M. Contreras-Macazana, Moisés Apolaya-Segura, Cristian Díaz-Vélez, Jorge L. Maguiña   +11 more
doaj   +1 more source

Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination

Frontiers in Bioscience-Landmark, 2022
Background: In response to the outbreak of coronavirus disease 2019 (COVID-19) worldwide, inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are implemented.
Jie Jiao, Yang Shen, Pan Wang, Kun Zuo, Xinchun Yang, Mulei Chen, Ying Dong, Jing Li   +7 more
doaj   +1 more source

COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis [PDF]

, 2022
The addictive protection against SARS-CoV-2 reinfection conferred by vaccination, as compared to natural immunity alone, remains to be quantified. We thus carried out a meta-analysis to summarize the existing evidence on the association between SARS-CoV ...
Acuti Martellucci, Cecilia, Baccolini, Valentina, De Vito, Corrado, Flacco, Maria Elena, Manzoli, Lamberto, Renzi, Erika, Villari, Paolo   +6 more
core   +4 more sources

From Immunization to Autoimmunity: A Deep Dive Into Post‐COVID‐19 Vaccine Reactions—A Narrative Review

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Coronavirus disease‐2019 (COVID‐19) emerged in 2019 from Wuhan, China, leading to the accelerated development of vaccines, which have proven instrumental in controlling the spread of the virus. While vaccination ceased the increasing trend of the viral infection, rare adverse autoimmune events emerged as important ...
Mohammad Javad Yousefi‐Hashemabad, Saeed Hashemi, Kiarash Saleki, Seyed Mohamad Kazem Nourbakhsh, Andia Saleki, Zahra Hassanzadeh, Abbas Azadmehr   +6 more
wiley   +1 more source

Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2

Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.
SARS‐CoV‐2 vaccine induces cellular immune response. T‐cells play a protective role for COVID‐19. ABSTRACT The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have
Valentina Tovar, Isaura Pilar Sánchez, María Teresa Rugeles, Natalia Andrea Taborda, Juan C. Hernandez   +4 more
wiley   +1 more source

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

Frontiers in Medicine, 2023
BackgroundLong-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 ...
Fahimeh Safarnezhad Tameshkel, Shabnam Abedin Dargoush, Bahareh Amirkalali, Saeedeh Javadi, Ali Ghiaseddin, Yousef Alimohamadi, Ali Basi, Mahin Jamshidi Makiani, Mahin Jamshidi Makiani, Farhad Zamani, Mohammad Hadi Karbalaie Niya, Mohammad Hadi Karbalaie Niya   +11 more
doaj   +1 more source

“Dracunculus against the dragon” Hungarian Prime Minister Viktor Orbán’s public vaccination as simultaneous enactment of public health and foreign policy [PDF]

, 2023
This article examines performativity in Hungarian Prime Minister Viktor Orbán’s February 2021 public vaccination against COVID-19 with the Sinopharm BBIBP-CorV vaccine. Following a discussion of the concept of performativity as it pertains to the subject
Marton, Péter, Matura, Tamás Attila, Somogyvári, Csendike   +2 more
core   +1 more source

Complement Hyperactivation Is Mediated by Alternative and Lectin Pathways During Early Phase of Severe Vaccination‐Omicron BA.5 Infection

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Complement temporal activation kinetics, activation pathways, and their relationship with thromboinflammation and antibody responses in severe vaccination‐COVID‐19 remains unclear. Based on a vaccinated‐infected cohort, we analyzed complement immune responses across mild to critical COVID‐19 cases by a dynamic model.
Jinpeng Cao, Gang Yang, Tingting Cui, Jian Qin, Deyi Huang, Shiqin Jin, Xiaoyun Yang, Mingzhu Huang, Xiaoling Su, Siyi Liu, Yingjiao Xia, Shidong Deng, Chengna Luo, Zhuxiang Zhao, Yunhui Zhang, Nanshan Zhong, Zhongfang Wang   +16 more
wiley   +1 more source

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity

Frontiers in Immunology, 2023
BackgroundPeople with multiple sclerosis (pwMS) on anti-CD20 therapies (aCD20) and fingolimod have shown inadequate humoral responses to COVID-19 vaccines.ObjectiveThe objective of the study was to pilot larger studies by demonstrating the safety and ...
Nahad Sedaghat, Nahad Sedaghat, Masoud Etemadifar, Noushin Lotfi, Farnaz Sayahi, Ahmad Chitsaz, Mehri Salari, Alireza Ghasemi Movaghar   +7 more
doaj   +1 more source

Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion [PDF]

, 2021
We believe that vaccination is just a way to eliminate or strongly stop the COVID-19. In this regard, there are several vaccines with different efficacy and side effects.
Arabsorkhi, Mohammad, Ghiasi, Nasrin, Sadighpour, Tella, Valizadeh, Rohollah   +3 more
core   +1 more source